



11888


Description

Messenger RNA encoding the receptor binding domain of the SARS-CoV-2 spike glycoprotein fused with the T4 fibrin domain.

Schematic



UTR = Untranslated region; sig = extended signal sequence of the S glycoprotein; S1S2 RBD = Receptor Binding Domain of the S glycoprotein; GS = glycine/serine-rich linker; Fibrin = trimerization domain of enterobacteria phage T4 fibrin; poly(A) = polyadenylate signal tail.



5'- capping structure

cap G^{1A2} = m⁷G⁺m^{3'}-5'-ppp-5'-Am^{2'}-3'-p-
[m⁷ = 7-CH₃; m^{3'} = 3'-O-CH₃; m^{2'} = 2'-O-CH₃;

-ppp- = -PO₂H-O-PO₂H-O-PO₂H)-; -p- = -PO₂H-]

m¹Ψ = 1-methyl-3'-pseudouridylyl

Table of features

Element	Description	Position
cap	A modified 5'-cap1 structure (m ⁷ G ⁺ m ^{3'} -5'-ppp-5'-	1-2



	Am)	
5'-UTR	5'-untranslated region derived from human alpha-globin RNA with an optimized Kozak sequence	3-54
sig	S glycoprotein signal peptide (extended leader sequence), which guides translocation of the nascent polypeptide chain into the endoplasmic reticulum.	55-102
S1S2 RBD	Codon-optimized sequence, encoding the Receptor Binding Domain (RBD) of the of the SARS-CoV-2 spike (S) glycoprotein.	103 - 708
GS	Sequence that codes for a short linker peptide consisting of the amino-acids glycine and serine.	709-735
Fibritin	Partial sequence of T4 fibritin (foldon), used as a trimerization domain.	736-858
3'-UTR	The 3'-untranslated region comprises two sequence elements derived from the amino-terminal enhancer of split (AES) mRNA and the mitochondrial encoded 12S ribosomal RNA, to confer RNA stability and high total protein expression.	859-1153
poly(A)	A 110-nucleotide poly(A)-tail consisting of a stretch of 30 adenosine residues, followed by a 10-nucleotide linker sequence and another 70 adenosine residues.	1154-1263

Sequence / Séquence / Secuencia

```

GAGAAΨAAAC ΨAGΨAΨΨΨ CΨGGΨCCCCA CAGACΨCAGA GAGAACCCGC 50
CACCAΨGΨΨΨ GΨGΨΨΨΨΨΨ ΨGCΨGCΨGC ΨCΨΨGΨGΨCΨ ΨCΨCAGΨGΨG 100
ΨGGΨGAGAYΨ ΨCCAAAΨAYΨ ACAAAΨCΨGΨ GΨCCAΨΨΨGG AGAAGΨGΨΨΨ 150
AAΨGCAACAA GAΨΨΨGCAΨC ΨGΨGΨAYGCA ΨGGAAYAGAA AAAGAAΨΨΨC 200
ΨAAΨΨGΨGΨG GCΨGAΨAYΨΨ CΨGΨGCΨGΨA ΨAAΨAGΨGCΨ ΨCΨΨΨΨΨCCA 250
CAΨΨΨAAAΨG ΨΨAYGGAGΨG ΨCΨCCAACAA AAΨΨAAAΨGA ΨΨΨAYGΨΨΨΨ 300
ACAAAΨGΨGΨ AYGCΨGAΨΨC ΨΨΨGΨGAYC AGAGGΨGAYG AAGΨGAGACA 350
GAΨΨGCCCCC GGACAGACAG GAAAAAΨΨGC ΨGAΨΨACAAΨ ΨACAAACΨGC 400
CΨGAΨGAYΨΨ ΨACAGGAYGΨ GΨGAYΨGCΨΨ GGAAYΨCΨAA ΨAAΨΨAYAGAY 450
ΨCΨAAAAGΨGG GAGGAAAΨΨA CAAΨΨAYCΨG ΨACAGACΨGΨ ΨΨAGAAAAΨC 500
AAAΨCΨGAAA CCΨΨΨΨGAAA GAGAYAYΨΨC AACAGAAAΨΨ ΨAYCAGGCΨG 550
GAΨCAACACC ΨΨGΨAAΨGGA GΨGGAAGGAY ΨΨAAΨΨGΨΨA ΨΨΨΨCCAΨΨA 600
CAGAGCΨAYG GAΨΨΨCAGCC AACCAAYGGΨ GΨGGGAYAYC AGCCAΨAYAG 650
AGΨGGΨGGΨG CΨGΨCΨΨΨΨG AACΨGCΨGCA ΨGCACCΨGCA ACAGΨGΨGΨG 700
GACCΨAAAGG CΨCCCCCGGC ΨCCGGCΨCCG GAΨCΨGGΨΨA ΨAYΨCCΨGAA 750
GCΨCCAAGAG AYGGGCAAGC ΨΨACGΨΨCGΨ AAAGAYGGCG AAΨGGGΨAYΨΨ 800
ACΨΨΨCΨACC ΨΨΨΨAYGGCC GGΨCCCΨGGA GGΨGCΨGΨΨC CAGGGCCCCG 850
GCΨGAYGACΨ CGAGCΨGGΨA CΨGCAΨGCAC GCAAΨGCΨAG CΨGCCCCΨΨΨ 900

```



WHO
International Nonproprietary Names Programme

9/2020

CCCGΨCCΨGG	GΨACCCCGAG	ΨCΨCCCCGA	CCΨCGGGΨCC	CAGGΨAΨGΨ	950
CCCACCΨCCA	CCΨGCCCCAC	ΨCACCACCΨC	ΨGCΨAGΨΨCC	AGACACCΨCC	1000
CAAGCACGCA	GCAAΨGCAGC	ΨCAAAACGCΨ	ΨAGCCΨAGCC	ACACCCCCAC	1050
GGGAAACAGC	AGΨGAΨΨAAC	CΨΨΨAGCAAΨ	AAACGAAAGΨ	ΨΨAACΨAAGC	1100
ΨAΨACΨAACC	CCAGGGΨΨGG	ΨCAAΨΨΨCGΨ	GCCAGCCACA	CCCΨGGAGCΨ	1150
AGCAAAAAAAAA	AAAAAAAAAAAA	AAAAAAAAAAAA	AAAGCAΨAΨG	ACΨAAAAAAAA	1200
AAAAAAAAAAAA	AAAAAAAAAAAA	AAAAAAAAAAAA	AAAAAAAAAAAA	AAAAAAAAAAAA	1250
AAAAAAAAAAAA	AAA				1263

Ψ = 1-methyl-3'-pseudouridylyl